Novartis's paradigm-shifting, blockbusting heart failure drug trounces enalapril
This article was originally published in Scrip
Executive Summary
Novartis's novel heart failure therapy LCZ696 led to 20% fewer cardiovascular deaths, 21% fewer hospitalizations and a 16% reduction in all-cause mortality compared with the old mainstay, ACE inhibitor therapy enalapril, in the much-anticipated PARADIGM-HF study, in results that could change clinical practice and open up a $10bn market. A US filing for the product is planned by the end of this year, with an EU submission following in early 2015.